Zinc(II)—The Overlooked Éminence Grise of Chloroquine’s Fight against COVID-19?
Metadatos
Afficher la notice complèteEditorial
MDPI
Materia
COVID-19 SARS-CoV-2 2019-nCoV Zn(II) ionophores Chloroquine Hydroxychloroquine
Date
2020-09-01Referencia bibliográfica
Hecel, A.; Ostrowska, M.; Stokowa-Sołtys, K.; Wątły, J.; Dudek, D.; Miller, A.; Potocki, S.; Matera-Witkiewicz, A.; Dominguez-Martin, A.; Kozłowski, H.; Rowińska-Żyrek, M. Zinc(II)—The Overlooked Éminence Grise of Chloroquine’s Fight against COVID-19? Pharmaceuticals 2020, 13, 228. [doi:10.3390/ph13090228]
Patrocinador
National Science Center, Poland UMO-2017/26/A/ST5/00363 UMO-2017/26/A/ST5/00364Résumé
Zn(II) is an inhibitor of SARS-CoV-2′s RNA-dependent RNA polymerase, and chloroquine and hydroxychloroquine are Zn(II) ionophores–this statement gives a curious mind a lot to think about. We show results of the first clinical trials on chloroquine (CQ) and hydroxychloroquine (HCQ) in the treatment of COVID-19, as well as earlier reports on the anticoronaviral properties of these two compounds and of Zn(II) itself. Other FDA-approved Zn(II) ionophores are given a decent amount of attention and are thought of as possible COVID-19 therapeutics.